insights_auto
Por que 4142 subiu 2,14%?
Saiba maischevron_right
4142:TPE
Adimmune Corp
NT$ 16,70
arrow_upward
+2,14%(+0,35) 1D
9 de nov., 13:30:36 GMT+8 · TWD
search
Todos os ativos
| Códigos | Preço | Variação | % de variação |
|---|
insights_autoGerando os principais insights para 4142…
Abrir
NT$ 16,35
Alta
NT$ 17,00
Baixa
NT$ 16,35
Valor de mercado
7,17 bi
Volume médio
1,12 mi
Volume
721,37 mil
Alto — 52 sem
NT$ 22,50
Baixo — 52 sem
NT$ 15,65
LPA
-NT$ 0,34
Ações em circulação
235,29 mi
Nº de funcionários
564
Abrir
NT$ 16,35
Alta
NT$ 17,00
Baixa
NT$ 16,35
Valor de mercado
7,17 bi
Volume médio
1,12 mi
Volume
721,37 mil
Alto — 52 sem
NT$ 22,50
Baixo — 52 sem
NT$ 15,65
LPA
-NT$ 0,34
Ações em circulação
235,29 mi
Nº de funcionários
564
Notícias
De fontes da web e parceiros de notícias
InfoMoney
·
há 2 dias
Wall Street sob pressão: Nasdaq e S&P 500 caem pela 4ª semana; até onde podem recuar?
InfoMoney
·
há 10 horas
Dow Jones Futuro sobe em início de semana marcada por inflação e balanços de IA
New York Post
·
há 54 minutos
Dow surges 1,000 points after last week’s historic tech rout, while Jensen Huang’s Nvidia slumps
TradingView
·
há 48 minutos
Avalanche: Secures clearing and settlement role for NYSE-affiliated platform - 09 Nov 2026
Perfil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Sobre Adimmune Corp